MedTrace Logo

Exploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing

NCT06413212 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 55

Last updated 2025-06-04

No results posted yet for this study

Summary

To explore the consistency between result of PTC drug screening tests and actual clinical outcome for patients with advanced malignancy.

Conditions

Interventions

DIAGNOSTIC_TEST

Patient-derived tumor-like cell clusters (PTC) drug sensitivity testing.

Fresh malignant effusion samples were collected from advanced malignancy patients for PTC drug sensitivity testing, then assess the accuracy of this diagnostic test by combination and analysis with final clinical outcome.

Sponsors & Collaborators

  • Beijing GeneX MedLab Co., Ltd

    collaborator INDUSTRY

  • Liu Huang

    lead OTHER

Principal Investigators

  • Liu Huang · Tongji Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-04
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06413212 on ClinicalTrials.gov